Companies › Sana Biotechnology
1 active drug program in 26 registered trials: 13 Phase 2, 8 Phase 1, 3 Phase 4, 2 Phase 3; Neurology, Genitourinary, Hematology, Immunology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lornoxicam (SC291) Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Lupus Erythematosus; Non Hodgkin's Lymphoma; Non Hodgkin Lymphoma; Preterm Premature Rupture of Membrane … | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06396078 | Lornoxicam (SC291) | Phase 4 | Preterm Premature Rupture of Membrane | Other | Dec 2026 |
| NCT05257018 | Lornoxicam (SC291) | Phase 2 | Diffuse Large B-cell Lymphoma | Oncology | Dec 2026 |
| NCT05696093 | Lornoxicam (SC291) | Phase 3 | Ventilator Associated Pneumonia | Respiratory | Dec 2026 |
| NCT06098326 | Lornoxicam (SC291) | Phase 2 | Myelodysplastic Syndromes | Hematology | Dec 2026 |
| NCT06060782 | Lornoxicam (SC291) | Phase 1 | Burkitt Lymphoma | Oncology | Dec 2026 |
| NCT05126849 | Lornoxicam (SC291) | Phase 2 | Refractory Idiopathic Aplastic Anemia | Hematology | Jan 2027 |
| NCT04959175 | Lornoxicam (SC291) | Phase 1 | Hematologic Neoplasms | Oncology | Apr 2027 |
| NCT01192555 | Lornoxicam (SC291) | Phase 1 | Neuroblastoma | Oncology | Jun 2027 |
| NCT05470491 | Lornoxicam (SC291) | Phase 1 | HIV | Oncology | Jul 2027 |
| NCT06486337 | Lornoxicam (SC291) | Phase 2 | NHL | Oncology | Aug 2027 |
| NCT06425133 | Lornoxicam (SC291) | Phase 2 | Metastatic Colorectal Cancer | Oncology | Sep 2027 |
| NCT04576143 | Lornoxicam (SC291) | Phase 2 | HER2-negative Breast Cancer | Oncology | Sep 2027 |
| NCT06800391 | Lornoxicam (SC291) | Phase 2 | Pseudomyxoma Peritonei | Oncology | Nov 2027 |
| NCT06294236 | Lornoxicam (SC291) | Phase 1 | Lupus Erythematosus | Immunology | Dec 2027 |
| NCT05544565 | Lornoxicam (SC291) | Phase 4 | Pyelonephritis Acute | Genitourinary | Jan 2028 |
| NCT07652879 | Lornoxicam (SC291) | Phase 2 | POEMS Syndrome | Neurology | Jan 2028 |
| NCT07484633 | Lornoxicam (SC291) | Phase 4 | Infection | Infectious disease | Aug 2028 |
| NCT06176027 | Lornoxicam (SC291) | Phase 1 | Relapsed Peripheral T-Cell Lymphomas | Oncology | Sep 2028 |
| NCT06285422 | Lornoxicam (SC291) | Phase 1 | Non Hodgkin's Lymphoma | Oncology | Mar 2029 |
| NCT06819592 | Lornoxicam (SC291) | Phase 3 | All-cause Mortality | Neurology | Aug 2029 |
| NCT05462613 | Lornoxicam (SC291) | Phase 2 | Metastatic Colorectal Cancer | Oncology | Nov 2029 |
| NCT07768436 | Lornoxicam (SC291) | Phase 2 | Adenocarcinoma of the Breast | Oncology | Aug 2030 |
| NCT02579967 | Lornoxicam (SC291) | Phase 2 | Primary T-cell Immunodeficiency Disorders | Infectious disease | Dec 2031 |
| NCT07214688 | Lornoxicam (SC291) | Phase 2 | Allogeneic Stem Cell Transplant Recipient | Other | Jan 2032 |
| NCT03852407 | Lornoxicam (SC291) | Phase 2 | Acute Myeloid Leukemia in Remission | Oncology | Nov 2033 |
| NCT05878184 | Lornoxicam (SC291) | Phase 1 | Non Hodgkin Lymphoma | Oncology | Nov 2038 |
Cash and short-term investments of $122m on 2026-09-30; operating cash outflow about $146m a year; runway about 10 months at that burn, to Jul 2027; 4 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
ZetrOZ Caribou Biosciences Laboratorios Silanes S.A. de C.V. Brainfarma Industria Química e Farmacêutica S/A AFT Pharmaceuticals Sirnaomics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.